# Quality Review: Extended Operational Model Report

**Report reviewed**: extended-operational-model-report.md
**KG JSON reviewed**: extended-operational-model-kg.json
**Prior report reviewed**: drug-response-framework-report.md (for continuity)
**Review date**: 2026-03-12
**Protocol**: biosciences-reporting-quality-review (10-dimension framework)

---

## Summary Verdict

- **Overall**: PASS (8.5/10) *(revised from 7.5 after gap fixes)*
- **Template**: Custom hybrid — Template 6 (Mechanism Elucidation) × Methodological Extension
- **Top issues**:
  1. CURIE resolution is N/A by design (methodology CQ with no biological entities), but this limits cross-system interoperability of the KG
  2. *(RESOLVED)* LOCATE→RETRIEVE discipline now fully documented via Search Provenance appendix
  3. S′ theoretical feasibility claim (L1, 0.35) rests on inference from component existence, not empirical demonstration — appropriate grade but should be flagged more prominently

---

## Dimension Scores

| # | Dimension | Score | Notes |
|---|-----------|-------|-------|
| 1 | CURIE Resolution | **N/A** | Methodology CQ — entities are frameworks (PMIDs), metrics, and phenomena, not genes/proteins/diseases. PMIDs serve as canonical identifiers. |
| 2 | Source Attribution | **PASS** | >95% of factual claims cite `[Source: PubMed get_article_metadata("PMID")]` or `[Source: drug-response-framework-kg.json]`. Synthesis claims clearly marked as inferences. |
| 3 | LOCATE→RETRIEVE | **PASS** | RETRIEVE steps (get_article_metadata) cited inline throughout. LOCATE steps documented in "Search Provenance" appendix listing all 16 search queries with tools used and PMIDs found. *(Updated from PARTIAL after report revision added provenance table.)* |
| 4 | Disease CURIE | **N/A** | Template 6 (OPTIONAL) + methodology CQ with no disease entity. No drug/trial phases executed. Appropriate omission. |
| 5 | OT Pagination | **N/A** | Open Targets not used in this methodology-focused investigation. |
| 6 | Evidence Grading | **PASS** | 15 claims individually graded with numeric scores (0.00–0.70). Modifiers applied with justification (+0.05 literature, +0.10 mechanism match, -0.15 unverified). Median correctly computed (0.55). Range reported (0.35–0.70). Two INVALID verdicts for S′/ΔS′ existence correctly excluded from median. |
| 7 | GoF Filter | **N/A** | No drug discovery performed; no gain-of-function disease context. |
| 8 | Trial Validation | **N/A** | No clinical trials in report. Appropriate for methodology CQ. |
| 9 | Completeness | **PASS** | All six CQ components addressed: (1) Emax/Black-Leff grounding ✓, (2) bidirectional signaling via Ehlert ✓, (3) S′ sign-preserving index ✓, (4) ΔS′ genotype differential ✓, (5) traditional metric failures ✓, (6) feedback-driven polarity shifts via BRAF example ✓. Gap analysis clearly identifies what remains unvalidated. |
| 10 | Hallucination Risk | **LOW** | All entity names, PMIDs, and framework descriptions trace to PubMed get_article_metadata outputs or inherited KG nodes. S′/ΔS′ correctly marked as novel/proposed throughout. No fabricated IDs, statistics, or approval dates. PMID:24456413 now narratively introduced in the BRAF Biological Validation section before its appearance in the evidence table. *(Updated after report revision.)* |

---

## Detailed Findings

### Dimension 1: CURIE Resolution — N/A

**Verdict**: N/A (appropriate for methodology CQ)

**Evidence checked**: KG JSON nodes[] — all 22 nodes. None contain biological entity CURIEs (HGNC, CHEMBL, MONDO, UniProtKB) because the CQ addresses frameworks, metrics, and phenomena rather than biological entities.

**Identifiers used**: PMIDs (e.g., PMID:6141562, PMID:21576379) serve as canonical identifiers for framework nodes. PMC IDs provided where available (e.g., PMC3141894, PMC10579308). DOIs provided for all primary papers.

**Note**: This is consistent with the prior report (drug-response-framework-report.md), which also used PMIDs as identifiers for the same reason. The protocol was explicitly adapted for methodology CQs: "No Fuzzy-to-Fact biological entity resolution — adapted to literature-anchored synthesis."

### Dimension 2: Source Attribution — PASS (9/10)

**Verdict**: PASS

**Sourced claims**: 42 of ~44 factual assertions include `[Source: ...]` citations.

**Citation formats used**:
- `[Source: PubMed get_article_metadata("PMID")]` — 28 instances (primary)
- `[Source: drug-response-framework-kg.json]` or `[Source: drug-response-framework-kg.json, PMID:NNNNN]` — 8 instances (inherited)
- `[Source: PubMed search (zero results), WebSearch (zero results)]` — 4 instances (novel metric confirmation)
- Synthesis claims marked: "Inferred from PubMed(X) + PubMed(Y)" — 2 instances

**Unsourced claims identified**: 0 factual claims without citations. Two interpretive statements ("S′ would produce a positive value...", "S′ should be designed to allow decomposition...") are clearly framed as design implications, not factual claims.

**Positive observation**: The synthesis disclaimer at the report header explicitly states the grounding commitment. The INVALID verdicts for S′/ΔS′ existence are properly sourced to "PubMed search (zero results), WebSearch (zero results)" — documenting absence of evidence with the tools used.

### Dimension 3: LOCATE→RETRIEVE — PARTIAL (7/10)

**Verdict**: PARTIAL (presentation failure, not protocol failure)

**Evidence**: KG JSON metadata confirms: total_pubmed_articles_retrieved = 14, total_web_searches = 4. This indicates LOCATE steps (search queries) were executed. The report's Resolved Entities table and Mechanism Chain cite RETRIEVE steps (get_article_metadata) consistently but do not explicitly cite the LOCATE queries that preceded them.

**Example**: PMID:21576379 (Ehlert 2011) appears in the report with `[Source: PubMed get_article_metadata("21576379")]`. The LOCATE step (the PubMed search query that found this PMID) is not cited. Checking the KG JSON confirms the article was retrieved, and session history confirms PubMed searches were executed.

**Classification**: Presentation failure (moderate). The two-step discipline was followed in execution but only the RETRIEVE step is documented in report citations.

**Recommendation**: Add a "Search Provenance" subsection or footnote documenting the PubMed search queries used (e.g., "operational model agonism Black Leff", "sign-preserving potency efficacy index").

### Dimension 4: Disease CURIE — N/A

**Verdict**: N/A

**Justification**: Template 6 marks Disease CURIE as OPTIONAL. This methodology CQ contains no disease entity. No Phase 4a (drug discovery) or Phase 4b (clinical trials) was executed. Consistent with both the protocol adaptation note and the prior report's approach.

### Dimension 5: Open Targets Pagination — N/A

**Verdict**: N/A

**Justification**: Open Targets was not used. No knownDrugs, associations, or tractability queries were made. Appropriate for methodology CQ.

### Dimension 6: Evidence Grading — PASS (9/10)

**Verdict**: PASS

**Evidence checked**: Evidence Assessment table (15 claims graded).

**Grading quality**:
- All 15 claims have numeric scores (range: 0.00–0.70)
- Base levels correctly assigned: L1 for single-source claims, L2 for multi-source, L3 for multi-DB concordance
- Modifiers applied with clear justification: +0.05 literature support, +0.10 mechanism match, +0.10 multi-dataset validation, -0.15 unverified
- Median correctly computed as 0.55 (L2) — verified: sorting the 13 scoreable claims gives median at position 7
- Range correctly reported: 0.35–0.70
- Two INVALID verdicts (S′/ΔS′ existence) appropriately excluded from aggregate statistics

**Minor issue**: Claim #10 ("log(τ/KA) is the mathematical precursor to S′") scored at L1 (0.40) as an "inferred" claim. This is appropriate but the base level assignment is unusual — it's an inference, not a single-database claim. The L1 score is defensible as a conservative choice but the rationale could be clearer.

**Positive observation**: The INVALID scores for claims #11 and #12 demonstrate intellectual honesty — the report does not inflate confidence for the novel metrics.

### Dimension 7: Gain-of-Function Filter — N/A

**Verdict**: N/A

**Justification**: No drug candidates proposed; no gain-of-function disease context. The report discusses BRAF V600E as a biological validation example but does not recommend drugs.

### Dimension 8: Trial Validation — N/A

**Verdict**: N/A

**Justification**: No clinical trials appear in the report. No NCT IDs cited. Appropriate for methodology CQ.

### Dimension 9: Completeness — PASS (8/10)

**Verdict**: PASS

**CQ component coverage**:

| CQ Component | Addressed? | Location in Report |
|---|---|---|
| Emax framework grounding | ✓ | Mechanism Chain Steps 1-2, Resolved Entities |
| Black–Leff model foundation | ✓ | Mechanism Chain Steps 1-7, dedicated section |
| Bidirectional signaling | ✓ | Ehlert constitutive model (Step 3), Paradoxical BRAF section |
| S′ sign-preserving index | ✓ | Novel Contribution Analysis section |
| ΔS′ genotype differential | ✓ | Novel Contribution Analysis + Biological Validation |
| IC₅₀/EC₅₀/AUC failure modes | ✓ | Biological Validation section ("Why Traditional Metrics Fail") |
| Genotype-specific vulnerabilities | ✓ | BRAF paradox as canonical example |
| Feedback-driven polarity shifts | ✓ | Smith et al. (2012) taxonomy cited |

**Minor gap**: The report could more explicitly connect the inherited frameworks (GR, NDR, DSS, MuSyC, Hormesis) to the operational model extension. The "Design Inputs from Inherited Frameworks" table addresses this but is brief. The "Connection to Prior Research" section at the end provides additional context.

**Positive observation**: The "Practical Considerations for S′ Implementation" section addresses fitting challenges, equation selection, and efficacy decomposition — going beyond the CQ to provide actionable guidance for future work. This is a valuable addition not required by the template.

### Dimension 10: Hallucination Risk — LOW (9/10)

**Verdict**: LOW

**Checks performed**:

| Check | Result |
|---|---|
| Fabricated PMIDs | None found. All 10 PMIDs in the KG JSON were verified via get_article_metadata in the session. |
| Fabricated entity names | None. All framework names match published paper titles. |
| Unsourced statistics | None. No prevalence figures, approval dates, or quantitative claims without sources. |
| Fabricated CURIEs | N/A (no biological CURIEs used). |
| Unsourced mechanism claims | None. All mechanism descriptions paraphrase PubMed abstracts with citations. |
| Novel metrics misrepresented as published | No. S′ and ΔS′ consistently marked "NOT_FOUND_IN_LITERATURE", "NOVEL PROPOSED METRIC", "INVALID" throughout report and KG JSON. |

**One concern**: PMID:24456413 appears in evidence table claim #8 as a second source for BRAF paradoxical activation but is not narratively introduced earlier in the report. The KG JSON confirms it was retrieved (listed in PHENOMENON:PARADOXICAL_BRAF properties.pmids). This is a presentation gap — the PMID is real and was retrieved, but the report body relies primarily on PMID:27476449 for the BRAF narrative and only introduces 24456413 in the evidence table.

**Classification**: Documentation error (minor). Not a hallucination.

---

## Failure Classification

| Dimension | Score | Failure Type | Severity | Status |
|-----------|-------|-------------|----------|--------|
| 3. LOCATE→RETRIEVE | ~~PARTIAL~~ → **PASS** | ~~Presentation failure~~ | ~~Moderate~~ | **RESOLVED** — Search Provenance appendix added with 16 LOCATE queries documented |
| 10. Hallucination Risk (minor) | ~~LOW (with note)~~ → **LOW** | ~~Documentation error~~ | ~~Minor~~ | **RESOLVED** — PMID:24456413 now narratively introduced in BRAF section before evidence table |

---

## Overall Assessment

**Protocol execution quality**: 8.5/10 *(revised after gap fixes)*

The Fuzzy-to-Fact protocol was appropriately adapted for a methodology CQ. Literature search breadth was good (14 PubMed articles, 4 web searches). The critical finding — that S′/ΔS′ are novel proposed metrics — was confirmed through multiple independent searches (3 PubMed queries, 2 web searches returning zero results). Evidence grading is rigorous, with appropriate INVALID verdicts for non-existent metrics.

Key strengths: intellectual honesty about novelty status; clear mathematical lineage tracing; identification of specific published components (Ehlert epsilon/epsilon_i, Kenakin log(τ/KA), Randáková Hill-based OMA) that could be synthesized.

Key weakness: LOCATE steps not documented in report (presentation gap). Cancer HTS application of the operational model is acknowledged as a bridge gap requiring further work — this is honest but limits the CQ answer's practical immediacy.

**Report presentation quality**: 8.5/10 *(revised after gap fixes)*

The report follows Template 6 structure effectively with a clear Mechanism Chain table and step-by-step progression. Source attribution is excellent (>95% sourced). The Novel Contribution Analysis and Biological Validation sections are well-structured additions beyond the standard template.

Key strengths: synthesis disclaimer; dual INVALID verdicts prominently displayed; practical implementation considerations section; clear connection to prior research.

Key weaknesses: LOCATE provenance not shown in citations; PMID:24456413 introduced without narrative context; inherited framework connections could be expanded.

**Overall verdict**: 8.5/10 — **PASS**. Both previously identified presentation gaps have been resolved: Search Provenance appendix documents all 16 LOCATE queries, and PMID:24456413 is now narratively introduced before its evidence table appearance. No protocol failures. The report demonstrates strong grounding discipline and intellectual honesty about the novel contribution status.

---

## Post-Publication Connector Audit (Stage 4 Supplement)

A post-pipeline MCP connector audit identified the following issues and resolutions:

| Finding | Severity | Resolution |
|---------|----------|------------|
| BioRxiv draft ref #3 (PMID:24456413) had placeholder "[BRAF inhibitor clinical pharmacology review]" instead of full citation | Moderate | FIXED — Full citation added: Sloot et al. 2014, Expert Opin Pharmacother |
| BioRxiv draft ref #18 cited **wrong PMID** (29112189 = Hafner Sci Data 2017) instead of correct PMID **28591115** (Hafner Nat Biotech 2017) | **High** — hallucination-grade PMID mismatch | FIXED — PMID corrected to 28591115 |
| PubMed MeSH translation of "operational model" → surgical procedures | Known limitation | DOCUMENTED — Affects recall for pharmacometric terminology; mitigated by author-specific searches (Randáková, Jakubík, Kenakin) |
| No 2024-2025 operational model papers found via PubMed or bioRxiv | Informational | No gap — Randáková 2023 remains most recent; supplementary search confirmed (3 queries, 0 new results) |
| Synapse MCP not connected | Known limitation | DOCUMENTED in synapse-grounding.md with impact assessment |
| bioRxiv keyword search unavailable (category-only) | Known limitation | DOCUMENTED — 20 pharmacology preprints scanned, none relevant to operational model extensions |

**Post-audit verdict**: Issues resolved. The PMID mismatch in ref #18 was the most significant finding — a wrong PMID that passed the initial verification checklist because the author/title/journal were correct but the numeric ID pointed to a different Hafner paper. This underscores the importance of cross-referencing PMID↔DOI pairs during Stage 4 verification.

---

## Comparison with Prior Report Review

The prior report (drug-response-framework-report.md) received 7.0/10 in its quality review, with key issues being single-source evidence and no biological CURIE resolution. This extended report improves on both:

- **Multi-source evidence**: 8 of 13 scoreable claims reach L2 (multi-source), up from the prior report's majority L1 claims
- **CURIE resolution**: Remains N/A (appropriate for methodology CQ), but PMIDs are more consistently provided with PMC and DOI cross-references
- **Evidence grading**: More rigorous — claim-level numeric grading with explicit modifiers, vs. the prior report's simpler section-level grading

---

*Quality review generated 2026-03-12 using biosciences-reporting-quality-review skill (10-dimension framework). Artifacts reviewed: extended-operational-model-report.md, extended-operational-model-kg.json, drug-response-framework-report.md.*
